In his role, Lusk will lead the national sales force, manage international distribution, and drive activities to market the Celerus Wave System, the first and only solution to deliver precise, standardized immunohistochemistry (IHC) results in 15 minutes.

“The addition of Mr. Lusk reflects the response our system is receiving in the marketplace and progress we’ve made since our launch late last year. Celerus is already establishing a dominant position in rapid staining for various pathology applications,” said chief executive officer Dave Gross. “His extensive IVD background will serve Celerus very well, and subsequently our customers. His expertise in both IHC products and applications is unparalleled.”

“The Wave System is a revolutionary product that will forever change IHC and how anatomic pathology results are used,” Lusk said. “The applications currently emerging to take advantage of rapid and intraoperative IHC have very exciting implications for patient care and tremendous market potential.”

“We’re at a very exciting and fast-paced time in our history,” said Gross. “Adding Jason to our team, with his tremendous knowledge of our market, will help move Celerus toward industry leadership.”